WMS Partners’s Novavax NVAX Stock Holding History

WMS Partners’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-600	Closed	-$55K	–	244
2014 Q2	$55K	Buy	+600	New	+$52.7K	0.01%	238

Other funds holding NVAX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

WMS Partners's NVAX Position: Q3 2014 in Review

WMS Partners sold out of Novavax (NVAX) in Q3 2014, closing a stake of 600 shares — an estimated $55K sold.

WMS Partners first reported a position in NVAX in Q2 2014 and held it in 1 quarter. The position peaked at $55K in Q2 2014. 143 funds tracked by Wall St. Rank hold NVAX as of Q3 2014.

WMS Partners reported no remaining Novavax position as of Q3 2014 after selling out during the quarter.
WMS Partners sold 600 Novavax shares in Q3 2014, an estimated $55K.
WMS Partners first reported a position in Novavax in Q2 2014 and held it in 1 quarter.
WMS Partners's Novavax position peaked at $55K in Q2 2014.
143 funds tracked by Wall St. Rank held Novavax as of Q3 2014.

Based on WMS Partners's 13F filing for Q3 2014, filed 17 Nov 2014.